Cefotaxime and ceftriaxone use evaluation in pediatrics

DIACN MICROBIOL INFECT ms %%5;22:231-233 @ 1995 Elsevier ?kience Inc. 655 Avenue of the Americas, New York, NY lOOlO

axone were i

ns was ini~ate

onth

and 100% physician accep-

January February March April May June WY AUgWil September October December January-June

e reasons for drug use at the baseline assessment are summarized in Table 1. The most common reason was empiric treatment of Suspected sepsis (51.3%).

July-December

3342 3127 1257 919 386 2037 669 769

66.4 65.0 75.8 55.8 55.2 55.8 25.7 24.0 14.6 46.9” 18.9 25.5

25,125 6035

62.3 25.0b

50% of this was attributed to two older patients who received high ceftriaxone doses far long durations. bpracticefactor = 0.741 (l-0.259).

xone versus